Technical Analysis for CAPR - Capricor Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.62 -1.59% -0.01
CAPR closed down 1.59 percent on Thursday, January 17, 2019, on 34 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
6 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CAPR trend table...

Date Alert Name Type % Chg
Jan 17 MACD Bullish Centerline Cross Bullish 0.00%
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jan 17 Weak + Overbought Other 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.59%
Jan 16 1,2,3 Pullback Bullish Bullish Swing Setup -1.59%
Jan 16 Boomer Buy Setup Bullish Swing Setup -1.59%
Jan 16 Weak + Overbought Other -1.59%
Jan 16 Inside Day Range Contraction -1.59%

Older signals for CAPR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
Is CAPR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 3 Wave's Phase 2/3 study for DMD candidate suvodirsen selected for FDA CID program
Jan 2 Small med firms see increased buying
Dec 31 B. Riley FBR sees 65% upside in Deciphera Pharma in premarket analyst action
Dec 28 The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO
Dec 27 The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
Dec 27 Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth
Dec 26 Capricor Therapeutics -2% on DMD trial halt
Dec 26 U.S. drug developer Capricor places Duchenne drug trial on hold
Dec 26 A Peek Into The Markets: US Stock Futures Up; Dow Futures Rise Over 100 Points
Dec 11 The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
See more CAPR news...
Indicators
Indicator Value
52 Week High 2.29
52 Week Low 0.31
Average Volume 134,396
200-Day Moving Average 1.0823
50-Day Moving Average 0.6826
20-Day Moving Average 0.5259
10-Day Moving Average 0.607
Average True Range 0.0761
ADX 33.68
+DI 28.1426
-DI 14.3621
Chandelier Exit (Long, 3 ATRs ) 0.4817
Chandelier Exit (Short, 3 ATRs ) 0.5383
Upper Bollinger Band 0.7272
Lower Bollinger Band 0.3246
Percent B (%b) 0.73
BandWidth 76.554478
MACD Line 0.0007
MACD Signal Line -0.0278
MACD Histogram 0.0285
Fundamentals Value
Market Cap 14.57 Million
Num Shares 23.5 Million
EPS -0.82
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 15.44
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.68
Resistance 3 (R3) 0.69 0.67 0.67
Resistance 2 (R2) 0.67 0.66 0.67 0.67
Resistance 1 (R1) 0.65 0.65 0.64 0.64 0.66
Pivot Point 0.63 0.63 0.63 0.63 0.63
Support 1 (S1) 0.61 0.62 0.60 0.60 0.58
Support 2 (S2) 0.59 0.61 0.59 0.57
Support 3 (S3) 0.57 0.59 0.57
Support 4 (S4) 0.56